{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T05:24:21Z","timestamp":1790918661910,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2004,5,1]],"date-time":"2004-05-01T00:00:00Z","timestamp":1083369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Emergency Medicine"],"published-print":{"date-parts":[[2004,5]]},"DOI":"10.1016\/j.annemergmed.2003.11.006","type":"journal-article","created":{"date-parts":[[2004,4,21]],"date-time":"2004-04-21T05:15:11Z","timestamp":1082524511000},"page":"580-584","source":"Crossref","is-referenced-by-count":70,"title":["Buprenorphine"],"prefix":"10.1016","volume":"43","author":[{"given":"Karl A","family":"Sporer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annemergmed.2003.11.006_BIB1","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1345\/aph.10421","article-title":"Opioid dependence treatment, including buprenorphine\/naloxone","volume":"36","author":"Raisch","year":"2002","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.annemergmed.2003.11.006_BIB2","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s11606-002-0041-6","article-title":"Policy progress for physician treatment of opiate addiction","volume":"17","author":"Merrill","year":"2002","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.annemergmed.2003.11.006_BIB3","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0376-8716(00)00162-9","article-title":"The economic costs of heroin addiction in the United States","volume":"61","author":"Mark","year":"2001","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.annemergmed.2003.11.006_BIB4","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1001\/jama.283.10.1337","article-title":"Treatment for opioid dependence: quality and access","volume":"283","author":"Rounsaville","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.annemergmed.2003.11.006_BIB5","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1001\/jama.280.22.1936","article-title":"Effective medical treatment of opiate addiction","volume":"280","author":"National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.annemergmed.2003.11.006_BIB6","doi-asserted-by":"crossref","first-page":"360","DOI":"10.7326\/0003-4819-138-4-200302180-00027","article-title":"Food and Drug Administration approval of buprenorphine-naloxone for office treatment of addiction [letter]","volume":"138","author":"Resnick","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.annemergmed.2003.11.006_BIB7","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1056\/NEJMcp013579","article-title":"Clinical practice: office-based treatment of opioid-dependent patients","volume":"347","author":"Fiellin","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annemergmed.2003.11.006_BIB8","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0376-8716(03)00055-3","article-title":"From morphine clinics to buprenorphine: regulating opioid agonist treatment of addiction in the United States","volume":"70","author":"Jaffe","year":"2003","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.annemergmed.2003.11.006_BIB9","doi-asserted-by":"crossref","first-page":"688","DOI":"10.7326\/0003-4819-137-8-200210150-00014","article-title":"New federal initiatives to enhance the medical treatment of opioid dependence","volume":"137","author":"Fiellin","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.annemergmed.2003.11.006_BIB10","unstructured":"Buprenorphinetraining from SAMSHA [Substance Abuse and Mental Health Services Administration Web site]. Available at buprenorphine.samhsa.gov. Accessed October 30, 2003."},{"key":"10.1016\/j.annemergmed.2003.11.006_BIB11","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0740-5472(02)00257-X","article-title":"Buprenorphine: blending practice and research","volume":"23","author":"Ling","year":"2002","journal-title":"J Subst Abuse Treat"},{"key":"10.1016\/j.annemergmed.2003.11.006_BIB12","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/clpt.1993.72","article-title":"Subjective and physiologic effects of intravenous buprenorphine in humans","volume":"53","author":"Pickworth","year":"1993","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.annemergmed.2003.11.006_BIB13","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/009127009703700106","article-title":"Bioavailability of sublingual buprenorphine","volume":"37","author":"Mendelson","year":"1997","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.annemergmed.2003.11.006_BIB14","first-page":"428","article-title":"Kinetics of respiratory depression in rats induced by buprenorphine and its metabolite, norbuprenorphine","volume":"281","author":"Ohtani","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.annemergmed.2003.11.006_BIB15","first-page":"505","article-title":"Comparative analysis of buprenorphine- and norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling","volume":"272","author":"Ohtani","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.annemergmed.2003.11.006_BIB16","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1016\/S0376-8716(03)00061-9","article-title":"Safety and health policy considerations related to the use of buprenorphine\/naloxone as an office-based treatment for opiate dependence","volume":"70","author":"Bridge","year":"2003","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.annemergmed.2003.11.006_BIB17","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/S0376-8716(03)00058-9","article-title":"Pharmacokinetics of the combination tablet of buprenorphine and naloxone","volume":"70","author":"Chiang","year":"2003","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.annemergmed.2003.11.006_BIB18","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0009-9236(96)90173-3","article-title":"Buprenorphine and naloxone interactions in opiate-dependent volunteers","volume":"60","author":"Mendelson","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.annemergmed.2003.11.006_BIB19","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s002130050804","article-title":"Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers","volume":"141","author":"Mendelson","year":"1999","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.annemergmed.2003.11.006_BIB20","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jama.285.1.45","article-title":"Deaths attributable to methadone vs buprenorphine in France [letter]","volume":"285","author":"Auriacombe","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.annemergmed.2003.11.006_BIB21","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1046\/j.1360-0443.2002.00215.x","article-title":"A randomized controlled trial of buprenorphine in the management of short-term ambulatory heroin withdrawal","volume":"97","author":"Lintzeris","year":"2002","journal-title":"Addiction"},{"key":"10.1016\/j.annemergmed.2003.11.006_BIB22","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0376-8716(95)01186-2","article-title":"A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence","volume":"40","author":"Johnson","year":"1995","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.annemergmed.2003.11.006_BIB23","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1046\/j.1360-0443.1998.9344753.x","article-title":"Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial","volume":"93","author":"Ling","year":"1998","journal-title":"Addiction"},{"key":"10.1016\/j.annemergmed.2003.11.006_BIB24","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S0002-9343(98)00194-6","article-title":"A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic","volume":"105","author":"O'Connor","year":"1998","journal-title":"Am J Med"},{"key":"10.1016\/j.annemergmed.2003.11.006_BIB25","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1056\/NEJM200011023431802","article-title":"A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence","volume":"343","author":"Johnson","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annemergmed.2003.11.006_BIB26","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1056\/NEJMoa022164","article-title":"Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone","volume":"349","author":"Fudala","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annemergmed.2003.11.006_BIB27","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0376-8716(00)00200-3","article-title":"Pain intolerance in opioid-maintained former opiate addicts: effect of long-acting maintenance agent","volume":"63","author":"Compton","year":"2001","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.annemergmed.2003.11.006_BIB28","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1136\/bmj.326.7386.442","article-title":"Strategies for preventing heroin overdose","volume":"326","author":"Sporer","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.annemergmed.2003.11.006_BIB29","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3109\/10826089609045806","article-title":"Methadone maintenance and addicts' risk of fatal heroin overdose","volume":"31","author":"Caplehorn","year":"1996","journal-title":"Subst Use Misuse"},{"key":"10.1016\/j.annemergmed.2003.11.006_BIB30","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1046\/j.1360-0443.2002.00189.x","article-title":"Trends in opiate and opioid poisonings in addicts in northeast Paris and suburbs, 1995-99","volume":"97","author":"Gueye","year":"2002","journal-title":"Addiction"},{"key":"10.1016\/j.annemergmed.2003.11.006_BIB31","first-page":"777","article-title":"Temgesic abuse [letter]","volume":"96","author":"Harper","year":"1983","journal-title":"N Z Med J"},{"key":"10.1016\/j.annemergmed.2003.11.006_BIB32","first-page":"72","article-title":"Abuse of buprenorphine [letter]","volume":"99","author":"Rainey","year":"1986","journal-title":"N Z Med J"},{"key":"10.1016\/j.annemergmed.2003.11.006_BIB33","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1046\/j.1360-0443.2002.00242.x","article-title":"Abuse of buprenorphine by intravenous injection: the French connection [letter]","volume":"97","author":"Tacke","year":"2002","journal-title":"Addiction"},{"key":"10.1016\/j.annemergmed.2003.11.006_BIB34","doi-asserted-by":"crossref","first-page":"425","DOI":"10.5694\/j.1326-5377.1984.tb108106.x","article-title":"A case of buprenorphine abuse","volume":"140","author":"Quigley","year":"1984","journal-title":"Med J Aust"},{"key":"10.1016\/j.annemergmed.2003.11.006_BIB35","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1046\/j.1360-0443.2001.96226710.x","article-title":"Injecting misuse of buprenorphine among French drug users","volume":"96","author":"Obadia","year":"2001","journal-title":"Addiction"},{"key":"10.1016\/j.annemergmed.2003.11.006_BIB36","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0376-8716(93)90036-P","article-title":"The misuse of buprenorphine and a buprenorphine-naloxone combination in Wellington, New Zealand","volume":"33","author":"Robinson","year":"1993","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.annemergmed.2003.11.006_BIB37","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1093\/jat\/22.6.430","article-title":"Buprenorphine-related deaths among drug addicts in France: a report on 20 fatalities","volume":"22","author":"Tracqui","year":"1998","journal-title":"J Anal Toxicol"},{"key":"10.1016\/j.annemergmed.2003.11.006_BIB38","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1046\/j.1360-0443.1998.93913859.x","article-title":"Six deaths linked to concomitant use of buprenorphine and benzodiazepines","volume":"93","author":"Reynaud","year":"1998","journal-title":"Addiction"},{"key":"10.1016\/j.annemergmed.2003.11.006_BIB39","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1176\/ajp.155.3.447-b","article-title":"Six deaths linked to misuse of buprenorphine-benzodiazepine combinations","volume":"155","author":"Reynaud","year":"1998","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.annemergmed.2003.11.006_BIB40","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1520\/JFS14667J","article-title":"Fatal intoxication following self-administration of a massive dose of buprenorphine","volume":"45","author":"Gaulier","year":"2000","journal-title":"J Forensic Sci"},{"key":"10.1016\/j.annemergmed.2003.11.006_BIB41","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0140-6736(88)92749-3","article-title":"Prolonged respiratory depression caused by sublingual buprenorphine","volume":"1","author":"Thorn","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.annemergmed.2003.11.006_BIB42","first-page":"1023","article-title":"The respiratory depressive effects of intravenous buprenorphine in patients in an intensive care unit","volume":"55","author":"Downing","year":"1979","journal-title":"S Afr Med J"},{"key":"10.1016\/j.annemergmed.2003.11.006_BIB43","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/j.1365-2044.1985.tb10903.x","article-title":"Postoperative pain relief with naloxone: severe respiratory depression and pain after high dose buprenorphine","volume":"40","author":"Schmidt","year":"1985","journal-title":"Anaesthesia"},{"key":"10.1016\/j.annemergmed.2003.11.006_BIB44","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1034\/j.1399-6576.2003.00201.x","article-title":"Serious overdoses involving buprenorphine in Helsinki","volume":"47","author":"Boyd","year":"2003","journal-title":"Acta Anaesthesiol Scand"},{"key":"10.1016\/j.annemergmed.2003.11.006_BIB45","first-page":"255","article-title":"Overdosage of buprenorphine: case report","volume":"89","author":"Banks","year":"1979","journal-title":"N Z Med J"},{"key":"10.1016\/j.annemergmed.2003.11.006_BIB46","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/clpt.1989.10","article-title":"Naloxone reversal of buprenorphine-induced respiratory depression","volume":"45","author":"Gal","year":"1989","journal-title":"Clin Pharmacol Ther"}],"container-title":["Annals of Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196064403012058?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196064403012058?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T15:43:19Z","timestamp":1585755799000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0196064403012058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,5]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004,5]]}},"alternative-id":["S0196064403012058"],"URL":"https:\/\/doi.org\/10.1016\/j.annemergmed.2003.11.006","relation":{},"ISSN":["0196-0644"],"issn-type":[{"value":"0196-0644","type":"print"}],"subject":[],"published":{"date-parts":[[2004,5]]}}}